192 related articles for article (PubMed ID: 15014014)
21. [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
Fujita F; Koike M; Fujita M
Gan To Kagaku Ryoho; 2002 Apr; 29(4):577-84. PubMed ID: 11977542
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
Sakurai R; Tomizawa Y; Yoshii A; Miura Y; Tsurumaki H; Kaira K; Sunaga N; Kawashima O; Hisada T; Yamada M; Saito R
Cancer Chemother Pharmacol; 2018 Jan; 81(1):103-109. PubMed ID: 29124327
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Carmichael J; Allerheiligen S; Walling J
Semin Oncol; 1996 Oct; 23(5 Suppl 10):55-9. PubMed ID: 8893883
[TBL] [Abstract][Full Text] [Related]
24. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
[TBL] [Abstract][Full Text] [Related]
25. Pharmacometabonomics Analysis Reveals Serum Formate and Acetate Potentially Associated with Varying Response to Gemcitabine-Carboplatin Chemotherapy in Metastatic Breast Cancer Patients.
Jiang L; Lee SC; Ng TC
J Proteome Res; 2018 Mar; 17(3):1248-1257. PubMed ID: 29385795
[TBL] [Abstract][Full Text] [Related]
26. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
27. Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Flaherty KT; Stevenson JP; Hahn SM; Redlinger M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):217-22. PubMed ID: 12811513
[TBL] [Abstract][Full Text] [Related]
28. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Sacchi A; Gasparri A; Gallo-Stampino C; Toma S; Curnis F; Corti A
Clin Cancer Res; 2006 Jan; 12(1):175-82. PubMed ID: 16397040
[TBL] [Abstract][Full Text] [Related]
29. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
31. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Hassan R; Broaddus VC; Wilson S; Liewehr DJ; Zhang J
Clin Cancer Res; 2007 Dec; 13(23):7166-71. PubMed ID: 18056197
[TBL] [Abstract][Full Text] [Related]
32. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Leggas M; Kuo KL; Robert F; Cloud G; deShazo M; Zhang R; Li M; Wang H; Davidson S; Rinehart J
Cancer Chemother Pharmacol; 2009 Mar; 63(4):731-43. PubMed ID: 18500521
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
[TBL] [Abstract][Full Text] [Related]
34. Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
van Putte BP; Grootenboers M; van Boven WJ; van Oosterhout M; Pasterkamp G; Folkerts G; Schramel F
Lung Cancer; 2009 Aug; 65(2):208-13. PubMed ID: 19097670
[TBL] [Abstract][Full Text] [Related]
35. A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer.
Tognoni A; Pensa F; Vaira F; Vigani A; Caness P; Sinaccio G; Pronzato P
J Chemother; 2002 Jun; 14(3):296-300. PubMed ID: 12120886
[TBL] [Abstract][Full Text] [Related]
36. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
37. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
38. Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
J Pharmacol Exp Ther; 2017 Mar; 360(3):445-456. PubMed ID: 28028124
[TBL] [Abstract][Full Text] [Related]
39. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Gandara DR; Lau DH; Lara PN; Edelman MJ
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):26-30. PubMed ID: 10960942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
